placebo + valdecoxib + valdecoxib
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Laparoscopic Cholecystectomy
Conditions
Laparoscopic Cholecystectomy, Pain
Trial Timeline
Nov 1, 2002 → Jul 1, 2003
NCT ID
NCT00661635About placebo + valdecoxib + valdecoxib
placebo + valdecoxib + valdecoxib is a phase 3 stage product being developed by Pfizer for Laparoscopic Cholecystectomy. The current trial status is completed. This product is registered under clinical trial identifier NCT00661635. Target conditions include Laparoscopic Cholecystectomy, Pain.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00650039 | Phase 3 | Completed |
| NCT00661635 | Phase 3 | Completed |
Competing Products
7 competing products in Laparoscopic Cholecystectomy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pudexacianinium chloride | Astellas Pharma | Phase 2 | 52 |
| SHR0410 Injection + SHR0410 Injection + Placebo | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Entereg + Entereg + placebo | Merck | Phase 2 | 52 |
| Rocuronium + Rocuronium | Merck | Approved | 85 |
| Rocuronium IV bolus 0.1 mg/kg guided by TOF that must remain between 1-3 during surgery + Rocuronium IV bolus 0.1 mg/kg guided by TOF 0/4 and PTC≤ 2 | Merck | Approved | 85 |
| etoricoxib 120 mg | Merck | Approved | 85 |
| N1539 + N1539 + N1539 + Ketorolac Tromethamine + Placebo | Alkermes | Phase 3 | 74 |